Navigation Links
Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014
Date:10/21/2013

SAN DIEGO, Oct. 21, 2013 /PRNewswire/ -- Arcturus Therapeutics, Inc., an industry leader in RNAi technologies for the treatment of rare orphan diseases, today announced it has secured $5 million in a Series A funding round led by multiple private capital, high net-worth investors from Canada, Japan and the United States.

(Logo: http://photos.prnewswire.com/prnh/20130531/MM24393LOGO)

The Series A funding, which comprised more than 90% of the Series Seed investors, will enable Arcturus to maintain its momentum, nominate its first clinical candidate in 2014, and recruit high caliber talent to expand its operations at the respected Janssen Labs in La Jolla, Calif.

Arcturus anticipates additional revenues in 2014 from its portfolio of Unlocked Nucleic Acid (UNA) intellectual property, wherein very broad claims were recently granted by the USPTO). Furthermore, Arcturus' best-in-class delivery technology will also contribute to the company's ability to nominate additional clinical candidates throughout 2014 as the organization expands its pipeline and brings RNAi technologies to a new level.  

"As we meet with investors and potential partners, we're excited to s
'/>"/>

SOURCE Arcturus Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology news :

1. Trovagene Announces Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference
2. Drug development venture links translational research, business to launch new therapeutics
3. UCLA scientists develop new therapeutics that could accelerate wound healing
4. FASEB SRC announces conference registration open for: Melatonin Biology: Actions & Therapeutics
5. NTU launches new centre to develop new eye-deas for occular therapeutics
6. Fred Hutchinson Cancer Research Center partners with GlaxoSmithKline to develop muscular dystrophy therapeutics
7. Magical state of embryonic stem cells may help overcome hurdles to therapeutics
8. Scripps Florida scientist awarded $1.5 million to design therapeutics with new RNA approach
9. Study of oceans past raises worries about their future
10. Identification of stem cells raises possibility of new therapies
11. New Geology study raises questions about long-held theories of human evolution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2015)... 24, 2015 Research and Markets ( ... "Global Iris Recognition Market 2015-2019" report to their ... Recognition market to grow at a CAGR of 23.5 ... covers the present scenario and the growth prospects of ... To calculate the market size, the report considers the ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
(Date:3/23/2015)... Mass , March 23, 2015 SoundView Technology ... of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView was ... user feedback on their experience with the Wocket in multiple ... at CVS, Whole Foods and other retailers, making both debit ... Kris Tuttle also says, "If the company meets their ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... shows that anti-microbial medications are a common cause of ... (ALF), with women and minorities disproportionately affected. While ALF ... is unlikely; however liver transplantation offers an excellent survival ... published in the December issue of Hepatology , ...
... SANTA CRUZ, CA--The Genome 10K Community of Scientists and BGI ... a plan to sequence the genomes of 101 vertebrate species ... 10,000 species to be sequenced by the Genome 10K Project. ... effort to gather specimens of thousands of animals from zoos, ...
... On Nov. 16, 2010, at the annual AHA meeting in ... Arnold M. Katz Basic Science Research Prize for Young Investigators. ... and molecular physiology, and a member of the McAllister Heart ... N. and Arnold M. Katz Prize is one of the ...
Cached Biology News:Study finds anti-microbials a common cause of drug-induced liver injury and failure 2Genome 10K Project announces first 101 species for genome sequencing 2Genome 10K Project announces first 101 species for genome sequencing 3
(Date:5/5/2015)... May 5, 2015  A group of biotechnology executives ... Coma Research Institute, a non-profit organization dedicated to providing ... suffering from disorders of consciousness.  ...   ... in which no voluntary actions can be initiated by ...
(Date:5/5/2015)... May 5, 2015 CytomX, a biotechnology company ... announced that Sean McCarthy , D. Phil., chief ... Day in New York at ... will present an overview of CytomX,s Probody pipeline, including ... programs. About CytomX Therapeutics CytomX Therapeutics ...
(Date:5/5/2015)...  Indianapolis-based medical device manufacturer NICO Corporation is ... products including the BrainPath® and Myriad™ technologies offering ... abnormalities and then removing affected tissue. More than ... 50 institutions throughout the United States ... in 12 abstracts, three peer-reviewed publications, and seven ...
(Date:5/4/2015)... /PRNewswire/ - JSS Medical Research Inc., a Montreal ... the acquisition of Max Neeman International (MNI), with head office in ... located in Ahmedabad, Bangalore , Chennai ... subsidiary, a regional office is located North Carolina, USA ... the recent equity investment transaction into JSS with Capital Croissance PME ...
Breaking Biology Technology:Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 3Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 4Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 5NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 2NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 3JSS Medical Canada widens its global presence across Asia/Pacific region 2JSS Medical Canada widens its global presence across Asia/Pacific region 3JSS Medical Canada widens its global presence across Asia/Pacific region 4
... about these days stirs as much feedback as my columns ... tools, search, social networks, and syndication technologies. , ,Over the ... social networks to a cautious blogger, and now an enthusiastic ... force that is fundamentally changing communications on every facet. , ...
... than ever before, experts at AD:TECH Chicago agreed, ... quickly sink a product or company's reputation. The result? More ... for companies to watch their brandsand their backs. , ,Several ... companies need to focus more on maintaining their online presence ...
... a rainbow arches from its HQ all the way to prison. ... sheds its old image of ENWRONG to PRISMA. After paying $665 ... identity of PRISMA while some of its executives walk to prison. ... a staff of 5000 in 25 different business units, a big ...
Cached Biology Technology:Changing perspectives on social networks 2Changing perspectives on social networks 3AD:TECH: Advertisers face harsh lessons at the hands of powerful consumers 2AD:TECH: Advertisers face harsh lessons at the hands of powerful consumers 3AD:TECH: Advertisers face harsh lessons at the hands of powerful consumers 4Why is Enron now called Prisma? 2Why is Enron now called Prisma? 3
Rat polyclonal to acetyl Salicylic Acid ( Abpromise for all tested applications)....
Drugs and NO-drug Rat Anti-conjugated Acetyl Salicylic Acid Polyclonal Antibody...
Rabbit polyclonal to UBC12 (rating: ****) ( Abpromise for all tested applications). Antigen: Synthetic peptide: RGGYIGSTYFER, corresponding to amino acids 169-180 of UBC12 Entrez Gene ID: 90...
GBL Antibody...
Biology Products: